Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. Show more
2749 East Parleys Way, Salt Lake City, UT, 84109, United States
Market Cap
82.21M
52 Wk Range
$1.37 - $4.20
Previous Close
$2.13
Open
$2.03
Volume
56,274
Day Range
$2.03 - $2.17
Enterprise Value
41.16M
Cash
43.3M
Avg Qtr Burn
-6.477M
Insider Ownership
10.63%
Institutional Own.
57.88%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|
